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Introduction: Treatment for post-traumatic stress disorder (PTSD) in combat veterans
that have a long-term positive clinical effect has the potential to modify the treatment
of PTSD. This outcome may result in changed and saved lives of our service personnel
and their families. In a previous before–after-intervention study, we demonstrated high
statistical and substantively significant short-term changes in the Clinician Administered
DSM-IV PTSD Scale (CAPS) scores after a 2-week trial of a subject’s particular novel brain
and vestibular rehabilitation (VR) program. The long-term maintenance of PTSD severity
reduction was the subject of this study.
Material andmethods:We studied the short- and long-term effectiveness of a subject’s
particular novel brain and VR treatment of PTSD in subjects who had suffered combat-
related traumatic brain injuries in terms of PTSD symptom reduction. The trial was
registered as ClinicalTrials.gov Identifier: NCT02003352. We analyzed the difference in
the CAPS scores pre- and post-treatment (1week and 3months) using our subjects as
their matched controls.
Results: The generalized least squares (GLS) technique demonstrated that with our 26
subjects in the 3 timed groups the R2 within groups was 0.000, R2 between groups
was 0.000, and overall the R2 was 0.000. The GLS regression was strongly statistically
significant z =21.29, p<0.001, 95% CI [58.7, 70.63]. The linear predictive margins over
time demonstrated strong statistical and substantive significance of decreasing PTSD
severity scores for all timed CAPS tests.
Discussion: Our investigation has the promise of the development of superior outcomes
of treatments in this area that will benefit a global society. The length of the treatment
intervention involved (2weeks) is less that other currently available treatments and has
profound implications for cost, duration of disability, and outcomes in the treatment of
PTSD in combat veterans.
Keywords: PTSD, vestibular rehabilitation, brain rehabilitation, off vertical axis rotation, DSM-IV CAPS
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Introduction
Treatment for post-traumatic stress disorder (PTSD) in com-
bat veterans that have a long-term positive clinical effect has
the potential to modify the treatment of PTSD. This outcome
may result in changed and saved lives of our service person-
nel and their families. In a previous before–after-intervention
study (1), we demonstrated strong statistical and substantively
significant short-term changes of the Clinician Administered
DSM-IV PTSD Scale (CAPS) scores (2) in a cohort of 98 com-
bat veterans after a 2-week trial of a subject’s specific novel
brain and vestibular rehabilitation (VR) program. The CAPS is
considered to be the gold standard for diagnosing PTSD and
assessing symptom severity (2, 3). Our sample was gathered
from around the United States and we noted a limitation of our
study specific to the gathering of long-term post-treatment CAPS
scores. The positive changes observed 1week post-treatment
resulted in increased activities of daily living including gain-
ful employment such that our subjects were not able to take
the time to travel to our facility for long-term (3-month post-
treatment) testing. We therefore decided to repeat our study
with a cohort of combat veterans with PTSD gathered from
our local clinical area in Dallas, TX, USA in order to facili-
tate the long-term outcomes testing. Combat veterans residing
near our clinic would not have the need for long distance travel
and time away from work and lifestyle. Mild traumatic brain
injury (mTBI) is the most prevalent injury (4) suffered by com-
bat troops in Iraq/Afghanistan and is significantly associated
with blast-related head injuries (5). In fact, service personnel
that have suffered mTBI have an increase in PTSD symptoms
(6, 7) and there is an elevated prevalence of both PTSD and
mTBI among combat veterans (8–10). We know that PTSD and
mTBI symptoms are interdependent and mutually influence one
another such that a reduction in PTSD symptoms is positively
associated with a reduction in post concussive symptoms (11).
However, vestibular complaints are the most frequent sequelae
of mTBI with VR established as the best treatment modality
(12, 13) that is central to our subject’s specific brain and VR
rehabilitation of PTSD (1). The PTSD Guideline Development
Group and the National Collaborating Centre for Mental Health
review team developed a guideline (NICE) based on best avail-
able evidence to advise on the treatment and management of
PTSD (14). NICE recommended three treatments (Selective sero-
tonin re-uptake inhibitors (SSRI), Eye movement desensitization
and reprocessing (EMDR) and trauma-focused cognitive behav-
ioral therapy (TF-CBT). A meta-analysis revealed that TF-
CBT is most effective of the three NICE recommended treat-
ments and was associated with the best outcome (15–17).
However, immediate post-treatment CAPS outcomes after a
2-week subject’s specific brain and VR treatment program
of PTSD after mTBI (1) are associated with strong substan-
tive and statistically significant decreases in PTSD severity.
The intervention that we investigated appears to be superior
to the NICE recommended treatments. The long-term main-
tenance of PTSD severity reduction was the subject of this
study.
Materials and Methods
Research Aims and Hypothesis
Research Question
What is the long-term effectiveness in terms of PTSD symp-
tom reduction of a 2-week subject’s specific novel brain and VR
treatment intervention in patients with PTSD who have suffered
combat-related traumatic brain injuries.
Hypothesis
A 2-week subject’s specific novel brain and VR treatment pro-
gram will be effective in PTSD symptom reduction shortly after
treatment and over time (1week and 3months post-treatment).
Preliminary Data
We searched a variety of databases for randomized controlled tri-
als of mTBI and PTSD and VR up until January 2015 without suc-
cess. Our search included Cochrane Injuries Group’s specialized
register, Cochrane Depression, Anxiety andNeurosis Group’s spe-
cialized register, Cochrane Central Register of Controlled Trials,
MEDLINE, PsycINFO, EMBASE, CINAHL, AMED, ERIC, and
PsycBITE. Our team has reported that a subject’s specific novel
a 2-week brain and VR treatment has resulted in strong statistical
and substantive significance in decreasing PTSD severity in com-
bat veterans (1) as measured by changes in CAPS DSM-IV scores.
We reported difficulty in obtaining long-term (3months) CAPS
DSM-IV outcome data due to geographical constraints and the
inability of subjects to return for testing associated with increased
work and social activities. We addressed these difficulties and
proposed a new study involving combat veterans with PTSD who
lived in the area of our Institutional Brain Center. The 2008 Insti-
tute of Medicine review of interventions research for PTSD con-
cluded that new, well-designed studies are needed to evaluate the
efficacy of treatments for PTSD (18). We had completed an initial
pilot project with great success and had the funding and patient
population to design and implement a long-term study. TBI may
reflect an overlap between brain regions vulnerable to traumatic
brain injury, and the neural circuitry of these disorders (19).
Research Design and Methods
The studywas approved by our Institutional IRB and conducted in
accordance with the principles of the Declaration of Helsinki. The
trial was registered with a service of the U.S. National Institutes of
Health as ClinicalTrials.gov Identifier: NCT02003352. There was
equipoise.
Study Design
This before–after short- and long-term intervention trial was
designed to identify the effectiveness of a subject’s specific novel
brain and VR treatment modality in patients with PTSD who
have suffered combat-related traumatic brain injuries. Subjects
served as their own matched controls. We accomplished the spe-
cific aim of our study by analyzing the difference in the CAPS
DSM-IV scores (2) pre and post 1 week and 3months treatment
in our subjects as outcomes to compare the effectiveness of the
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interventions. We expected immediate positive changes in the
outcomes after treatment, confirming the results of our previ-
ous study, as well as at follow-up over time, i.e., 3months after
cessation of the 2-week treatment period. One qualified licensed
psychologist who was blinded to all components of the study
conducted all CAPS testing. The study design included one pre-
treatment assessment and two post-treatment assessments (at
1 week and 3months). The study was performed at the Depart-
ment of Neurology of the Carrick Brain Center in Dallas, TX,
USA.
Sample Size
Our sample size calculations were based on obtaining a mod-
erately strong estimated effect size (ES) of differences in DSM-
IV CAPS scores over time (pre-treatment, 1 week post-treatment
and 3months post-treatment). Our pilot study (1) demonstrated
strong statistical and substantive significance of changes in CAPS
DSM-IV severity scores in a cohort of 98 subjects that had a pre-
treatment mean of 73.13 and a 1-week post-treatment mean of
58.14 (SD of the differences of 14.49 maintaining an α of 0.05
and a power of 80% with subjects serving as their own matched
control).We would need 10 subjects serving as their ownmatched
control in the present study if we were to address only the pre-
treatment and 1week post-treatment if our results were as strong
as those of our pilot study. However, this present study sample and
power calculation is specific to obtaining a moderately strong ES
between the pre and 1-week post-treatment CAPS DSM-IV and
the long-term 3-month outcomes. We had demonstrated strong
statistical and substantive significance in our pilot study and
decided that we would accept a long-term ES that was moderately
strong, expecting to see a decrease in the effect of the treatment
over time while still demonstrating significant statistical and sub-
stantive significance from the pre-treatment outcomes. We used
Cohen’s f (20) to measure the ES and calculate the power and
sample size in this study. Cohen’s f is the square root of the ratio of
theANOVAbetween-group to thewithin-group variances with an
f = 0.10 defined as a small ES, an f = 0.25 is defined as a medium
ES, and an f = 0.40 is defined as a large ES.We needed 3 groups of
26 subjects for a total of 78 subjects to obtain a moderately strong
ES of 0.3586 for a one-wayANOVA. This study designmaintained
a Type I error at an acceptable level of 0.05 in order to minimize
the risk of false positive findings with 80% power (Figure 1).
Participants
The study population consisted of 26 combat veterans who had
suffered a traumatic brain injury with PTSD and were referred to
our study by Veteran’s groups. All subjects were male with a mean
age of 38.54 years with a minimum age of 25 and a maximum age
of 58. They served as their own matched controls and composed
three groups of timed diagnostic testing (pre-treatment, 1-week
post-treatment, and 3-month post-treatment). They all met the
inclusion requirements and did not have any of the exclusion
requirements.
Inclusion Criteria
Military combat veterans who had suffered TBI and PTSD that
were exposed to war-zone events in Operation Enduring Freedom
FIGURE 1 | Estimated effect size for one-way ANOVA.
(OEF) and/or Operation Iraqi Freedom (OIF). Subjects fulfilled
all criteria for a diagnosis of chronic PTSD based on the DSM-IV
(21) with qualifying scores on the Clinician Administered PTSD
Scale (CAPS) (2). All subjects must have had previous treatments
for PTSD that was not successful. Subjects were 18 years of age or
older and were able to give written informed consent.
Exclusion Criteria
Presence of any of the following DSM-IV diagnoses: psychotic
disorder, mania, or bipolar disorder; current major depression
with psychotic features; current drug or alcohol or substance/drug
dependence; patients that are considered a suicidal risk.
Assessments and Outcome Measures
We used changes in the DSM-IV CAPS scores before and after
treatment (1week and 3months) to distinguish between the esti-
mated frequency and intensity of the various symptoms. Fre-
quency and intensity scores were combined to give a total CAPS
score (range: 0–136) as standard in the DSM-IV CAPS evaluation
procedures (2, 3). CAPS testing was scheduled pre-intervention,
1 week post-intervention, and at 3months post-intervention.
Intervention: Subject’s Specific Brain and
Vestibular Rehabilitation
We utilized the same subject’s specific novel brain and VR that we
reported in our pilot study (1). Our treatments are based upon
a combination of VR techniques that include combinations of
active and passive head movements in a variety of planes while
the subject maintained visual fixation on a target, off axis whole
body rotation, visual pursuit, and visual saccadic eye movements
to novel targets that are individualized and specific to each subject
(22–26). Although the treatment parameters are similar, they
are uniquely tailored from subject to subject. For example, one
subject might have a deficit of gaze holding in right gaze and
another in left gaze. Both would have gaze holding strategies
prescribed specific to their clinical needs, the first subject to the
right, and the second to the left. To avoid inter-rater variability,
the same clinician decided the treatment plan for all subjects. Our
clinical experience has shown that customized treatment based
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on reported symptoms and finding of physical and neurological
examination by trained clinicians is more effective than standard
VR treatment. Each subject received three daily sessions of VR
treatment modalities for 2weeks (five week days per week with
two weekend days off). Subjects were instructed to rest between
treatments. No medication changes were prescribed during the
treatment period. Clinicians certified in VR administered the
treatment. These clinicians did not know the results of the CAPS
pre-treatment evaluation.
Procedure
All subjects met the inclusion criteria at the referring agency
and then underwent a comprehensive medical history and neu-
rological examination as well as a CAPS test to confirm PTSD
after mTBI. They were carefully examined to ensure that they
did not meet any of the exclusion criteria. The subjects that were
acceptable to the study were given a detailed explanation of the
study and an offer to participate in the study after giving informed
consent. Participants underwent another CAPS test 1 week after
their treatment had been finished and were scheduled again at
3months post-treatment.
Statistical Analyses
A statistical analysis was conducted with Stata/SE 13.1 (StataCorp,
College Station, TX, USA) according to an intention-to-treat
(ITT) approach. Since it was expected that some participants
might not complete the study for a variety of reasons, the analysis
procedure included provisions for identifying these individuals
making a careful note of the reasons for no completion if possible.
However, compliance with treatment appointments was necessary
for the subject to be included in the analysis. An individual who
missed more than 25% of their treatment appointments would
be categorized as being non-compliant. Dropouts were to be
identified separately from those individuals who were deemed
non-compliant. The ANCOVA served as our design substitute
for randomization. The short-term efficacy of the treatment
modality was evaluated by considering the difference pre and
post (at 1 week after treatment) of the CAPS Total Severity Scores
for each subject (matched pairs) and by calculating the probability
of error (p value) by a two-tailed t-test for repeated measures
maintaining an α of<0.05. The ES was calculated in several ways
to ascertain if the difference between the matched pairs was both
statistically and clinically significant: as proposed by Cohen, the
ratio of the mean difference between the two groups (pre and
1week post) divided by the pooled variance of the groups was
calculated (27). Another ES as proposed by Hedges was calculated
using a formula similar to Cohen’s but calculating the SD using
N 1 instead ofN (whereN is the number of samples considered)
(28). In both cases, an ES value of 0.2 represents a small statistical
and clinical difference between two groups; an ES value of 0.5
represents amoderate difference; and an ES value of 0.8 represents
a large difference (27). The ES was also obtained by calculating
the point biserial correlation: a percent improvement between
CAPS Total Severity Score was calculated [(post test group mean
minus pre test group mean)/(pre test group mean) 100], the
changes between sequential CAPS scores were measured and how
FIGURE 2 | Figure 2 CAPS severity scores for each of the paired observations and the regression line fitting the values.
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strong the relationship was between them was calculated. In this
last case, a value of 0.01–0.09 is a small effect, a value of 0.10–0.25
is a medium effect and a value of over 0.25 represents a large ES.
Similar calculations were done to assess the long-term efficacy of
the treatment modality by considering the difference pre and post
(at 3months after treatment) of the CAPS Total Severity Scores
for each subject (matched pairs). We also used a multiple linear
regression model to predict and explain both the short- (1 week
post-treatment) and long-term (3month) outcomes and included
Eta Squared (η2) and Omega Squared (ω2) calculations of the ES.
We calculated the Eta Squared (η2) by taking the sum of squares
for a variable divided by the total sum of squares to reveal how
much of the variation in the sample was explained by the predic-
tor. Cohen (29) suggests that a value of η2 of 0.01 is a small ES, 0.06
ismedium, and 0.14 is large. Theω2 is an estimate of the explained
variable in the population and adjusts for degrees of freedom
and the error term, making it somewhat smaller than the η2. We
also calculated the Beta Weights (β) as a measure of the ES of the
multiple linear regression. β= 0.01 is a weak effect, β= 0.30 is a
moderate effect, and β= 0.50 is a strong effect. Furthermore, we
calculated the correlation between our timed tests (a correlation of
|r|= 0.1 is a weak relationship, |r|= 0.3 is a moderate relationship,
and |r|= 0.5 is a strong relationship). Finally, we used a repeated
measure ANOVA to evaluate the three groups over time in this
before–after-intervention study to ascertain if the intervention
was enduring as well as ANCOVA testing as an extension of our
multiple regression model. We desired to control for group differ-
ences that might influence the results because of our lack of ability
to randomize our sample. Residuals were analyzed for normalcy
and compared with predicted values to discern any possible
issues with our model. A residual-vs.-fitted plot was developed
to see if we could discern a pattern that would indicate that our
model has problems, and an Adjusted Partial Residual Plot using
regressors already in the model was used to better understand the
regression. Correlation between the CAPS scores over time was
calculated.
We also decided to use a bootstrap estimation of the SEs in the
linear regression. We drew 1000 random samples with replace-
ment from the dataset and examined the distribution of each
parameter using the variance of that distribution to estimate a SE.
Finally, we wanted to estimate any unknown parameters in
our linear regression model of our three treatment groups by
FIGURE 3 | Number of subjects for each of the categories of the CAPS DSM IV scores for each of the three testing sessions.
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using a random effects generalized least squares (GLS) tech-
nique and by doing an ANOVA of the changes in CAPS scores
over time.
Results
Our sample was composed of 26 males with a mean age of 38 that
served as their ownmatched controls in three groups representing
CAPS DSM-IV testing immediately pre-treatment (mean 77.58,
SD 18.45), 1 week post-treatment (mean 61.08, SD 17.29), and at
3months post-treatment (mean 55.38, SD 18.43). Figure 2 shows
the CAPS severity scores for each of the paired observations Pre –
1-week post; Pre – 3-month post; 1-week post – 3-month post, for
all the subjects as well as the regression line fitting the values. As
it is evident from the plot of the three superimposed fitted lines,
the regression line of the 1-week post – 3-month post pair has the
greater slope, whereas the one of the Pre – 3-month post pair has
the lower slope.
Figure 3 and Tables 1–3 show the number of subjects for
each of the categories of the CAPS DSM-IV scores (minimal,
mild, moderate, severe, extreme) for each of the three testing
sessions (pre-treatment, 1-week post-treatment, and 3-month
post-treatment). It is evident that the treatment is effective and the
number of subjects included in the last category (Extreme) gets
significantly smaller over time and there is a distribution of the
subjects toward lesser categories (less symptoms).
Figure 4 shows a graphical representation of the statistical
values (mean and box plot) for all the subjects for each of the
three testing sessions. It is immediately apparent that there is a
reduction in the severity of the CAPS scores from the pre to the
1-week post-treatment confirming the results previously obtained
(1), but also such reduction continues over time as measured by
the 3-month post CAPS scores.
This decrease in symptomsmeasured as reduction in the CAPS
Score is statistically significant: Table 4 includes the t-tests results
for each comparison (Pre – 1-week post; Pre – 3-month post;
1-week post – 3-month post) for all the subjects as well as for those
in themoderate, severe, and extreme categories of theCAPS scores
pre-treatment: only the moderate category is not significant, but
the results could be heavily affected by having only three subjects
in this category. The minimal (one subject pre-treatment) and
mild (no subjects pre-treatment) categories were not considered
separately given the small or inexistent number of subjects in these
categories.
Table 5 shows the ESs based on mean comparison for the Pre –
1-week post and the Pre – 3-month post-treatment groups of
CAPS scores. For the Cohen’s d and Hedges’s g, an ES value of 0.2
represents a small statistical and clinical difference between two
groups; an ES value of 0.5 represents amoderate difference; and an
ES value of 0.8 represents a large difference (27), and for the Point
Biserial r a value of 0.01–0.09 is a small effect, a value of 0.10–0.25
is a medium effect, and a value of over 0.25 represents a large
ES. Therefore, all three methods show a large difference or effect,
making the difference not only statistically, but also substantively
significant.
Our sample was not randomized and we used an analysis of
covariance (ANCOVA) and a multiple linear regression model
to statistically control for group differences that might influence
the result because we could not rule out these possible differences
through randomization. Therewas a strong statistically significant
TABLE 1 | Two way table with measures of association for the CAPS total severity scores pre and 1week post-treatment divided into each category
(minimal, mild, moderate, severe, and extreme) and their relative percentage.
Severity category pre Severity category post
Minimal Mild Moderate Severe Extreme Total
Minimal 0–19 1 0 0 0 0 1
100 0.00 0.00 0.00 0.00 100.00
100 0.00 0.00 0.00 0.00 3.85
Mild 20–39 0 0 0 0 0 0
0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00
Moderate 40–59 0 0 3 0 0 3
0.00 0.00 100.00 0.00 0.00 100.00
0.00 0.00 50.00 0.00 0.00 11.54
Severe 60–79 0 0 3 6 0 9
0.00 0.00 33.33 66.67 0.00 100.00
0.00 0.00 50.00 40.00 0.00 34.62
Extreme 80–136 0 2 0 9 2 13
0.00 15.38 0.00 69.23 15.38 100.00
0.00 100 0.00 60.00 100.00 50.00
Total 1 2 6 15 2 26
3.85 7.69 23.08 57.69 7.69 100.00
100.00 100.00 100.00 100.00 100.00 100.00
χ
2(12)=43.0667, p=0.000, ϕ=0.7431.
Key: frequency; row percentage; column percentage.
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TABLE 2 | Two way table with measures of association for the CAPS total severity scores pre and 3month post-treatment divided into each category
(minimal, mild, moderate, severe, and extreme) and their relative percentage.
Severity category pre Severity category post
Minimal Mild Moderate Severe Extreme Total
Minimal 0–19 1 0 0 0 0 1
100 0.00 0.00 0.00 0.00 100.00
50 0.00 0.00 0.00 0.00 3.85
Mild 20–39 0 0 0 0 0 0
0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00
Moderate 40–59 0 0 3 0 0 3
0.00 0.00 100.00 0.00 0.00 100.00
0.00 0.00 25.00 0.00 0.00 11.54
Severe 60–79 0 0 4 5 0 9
0.00 0.00 44.44 55.56 0.00 100.00
0.00 0.00 33.33 50.00 0.00 34.62
Extreme 80–136 1 1 5 5 1 13
7.69 7.69 38.46 38.46 7.69 100.00
50.00 100 41.67 41.67 100.00 50.00
Total 2 1 12 10 1 26
7.69 3.85 7.69 38.46 3.85 100.00
100.00 100.00 100.00 100.00 100.00 100.00
χ
2(12)=18.7407, p=0.095, ϕ=0.4902.
Key: frequency; row percentage; column percentage.
TABLE 3 | Two way table with measures of association for the CAPS total severity scores 1-week post and 3-month post-treatment divided into each
category (minimal, mild, moderate, severe, and extreme) and their relative percentage.
Severity category pre Severity category post
Minimal Mild Moderate Severe Extreme Total
Minimal 0–19 1 0 0 0 0 1
100 0.00 0.00 0.00 0.00 100.00
50 0.00 0.00 0.00 0.00 3.85
Mild 20–39 1 0 1 0 0 2
50.00 0.00 50.00 0.00 0.00 100.00
50.00 0.00 8.33 0.00 0.00 769
Moderate 40–59 0 0 4 2 0 6
0.00 0.00 66.67 33.33 0.00 100.00
0.00 0.00 33.33 20.00 0.00 23.08
Severe 60–79 0 1 6 8 0 15
0.00 6.67 40.00 53.33 0.00 100.00
0.00 100.00 50.00 80.00 0.00 57.69
Extreme 80–136 0 0 1 0 1 2
0.00 0.00 50.00 0.00 50.00 100.00
0.00 0.00 8.33 0.00 100.00 7.69
Total 2 1 12 10 1 26
7.69 3.85 46.15 38.46 3.85 100.00
100.00 100.00 100.00 100.00 100.00 100.00
χ
2(12)=34.2044, p=0.095, ϕ=0.5735.
Key: frequency; row percentage; column percentage.
difference between the means [F= (2,23)= 11.85 p< 0.001].
The ANCOVA and linear regression model predicted 51% of
the model (R2= 0.5075, Adjusted R2= 0.46). The SD around
the regression line is much smaller than the SD around the
mean [root mean squared error (MSE)= 13.49] and improves
our prediction. The regression equation allows us to estimate
the 3-month CAPS scores depending on the pre-treatment and
1-week post-treatment CAPS scores. A 1 point increase in the
pre-treatment CAPS score is associated with a decrease in the
3-month CAPS score of  0.04; however, this is not statistically
significant [t(23)= 0.83, p= 0.83]. The 95% confidence interval
has a range from  0.45 to 0.36 and contains a 0 signifying no
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FIGURE 4 | Caps DSM IV Severity Scores Over Time.
TABLE 4 | Two-tailed paired t-tests.
Groups Variable 1 Variable 2 T p
All subjects (26) Pre 1-week Post 5.72 0.0000*
Pre 3-month Post 5.84 0.0000*
1-week Post 3-month Post 2.13 0.0428*
Pre-treatment extreme (13) Pre 1-week Post 4.90 0.0004*
Pre 3-month Post 5.38 0.0002*
1-week Post 3-month Post 2.10 0.0578
Pre-treatment severe (9) Pre 1-week Post 5.62 0.0005*
Pre 3-month Post 4.86 0.0013*
1-week Post 3-month Post 0.25 0.8052
Pre-treatment moderate (3) Pre 1-week Post 3.90 0.0599
Pre 3-month Post 3.47 0.0741
1-week Post 3-month Post 1.14 0.3715
*The significant values.
TABLE 5 | Effect size based on mean comparison.
Groups Variable 1 Variable 2 Estimate 95% CI
Cohen’s d Pre 1-week Post 0.92 0.35–1.49
Pre 3-month Post 1.20 0.61–1.79
Hedges’s g Pre 1-week Post 0.91 0.34–1.47
Pre 3-month Post 1.19 0.60–1.76
Point Biserial r Pre 1-week Post 0.43 0.17–0.61
Pre 3-month Post 0.29 0.30–0.67
statistically significant relationship. An increase in the CAPS
score of 1 point on the 1-week post CAPS scores is associ-
ated with a decrease in the 3-month CAPS score of 0.79 points
with strong statistical significance (t(23)= 3.79, p< 0.001, CI
[0.3577556, 1.219584]). We are 95% confident that the interval
of 0.36–1.21 contains the true slope. We also calculated Beta (β)
weights as a measure of the ES and found that they were sub-
stantively significant with the pre-treatment β= 0.042 (moder-
ate) and the 1-week post-treatment β= 0.74 (extremely strong).
We wanted to see if the residuals were normally distributed.
Therefore, it appears that the CAPS score 1-week post-treatment
better correlates with the CAPS scores 3-month post-treatment
than the CAPS score pre-treatment. This has important clinical
consequences: the CAPS score pre-treatment is not an indication
of how the subject will respond to the subject specific brain
and VR therapy. However, as soon as the 2-week treatment reg-
imen is completed and the subject is evaluated 1-week post-
treatment, if there has been a change in the CAPS score over
such a short time, it is a good indication that not only the
subject will maintain such improvement but also that improve-
ment will be continuing over the next 3months. The skew-
ness of the residuals is  0.23 compared to the value of 0.00
for a normal distribution. The kurtosis is 2.16 compared with
the value of 3.00 for a normal distribution. Both the skewness
and kurtosis of the residuals were not significantly different
from what they would be if our residuals were normally dis-
tributed. p= 0.58 for Skewness and p= 0.33 for Kurtosis. This
was done because we wanted to look at the distribution of
residuals for the different predicted values to see if the resid-
uals were distributed similarly to the predicted values. There-
fore, after having verified that the residuals could be considered
normally distributed, the residual-vs.-fitted plot was developed
(Figure 5).
The model is well-fitted and there is no pattern to the residuals
plotted against the fitted values with no violation of the least-
squares assumptions. Note that where the fitted values are low
between 20 and 30, the residuals tend to be negative and where
the fitted values are moderate between 30 and 50 the residu-
als tend to be positive. The fitted values over 50 are associated
with residuals that tend to be similar to the predicted values
with the observations normally distributed for any fitted values
(x axis) about the reference line (residual of 0 on y axis). We
wanted to see how the residuals are distributed by graphing the
actual 3-month CAPS DSM-IV score on a predicted value for
this score. Using the component-plus-residual plot to assist in
projecting multidimensional data into a two-dimensional form
(Figure 5A), we can examine the functional form assumptions
of the model. The regression line through the coordinates has a
slope equal to the estimated coefficient in the regression model.
By looking at the residuals vs. predictor plots no specific patterns
comes to mind, indicating that the model considered takes into
account most of the phenomenon and the residuals are indeed
random. We then developed an Adjusted Partial Residual Plot
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FIGURE 5 | (A) CAPS DSM-IV component-plus-residual plot and residuals vs. fitted and (B) Residual vs. predicted plots.
FIGURE 6 | Adjusted partial residual plot.
using regressors already in the model to better understand the
regression (Figure 6). The regression of y on x has the same
coefficient and SE (up to a degree-of-freedom adjustment) as
the estimated coefficient and SE for the regressor in the original
regression. We are confidant that the residuals are normally
distributed and that our model is valid. The pre-treatment CAPS
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TABLE 6 | Linear predictive margins of CAPS over time with significance*.
Time Margin SE t p 95% CI
Pre-treatment 77.58 2.23 34.76 0.000* 73.09–82.06
1-week Post-treatment 61.08 2.23 27.37 0.000* 56.59–65.56
3 Months Post-treatment 55.38 2.23 24.82 0.000* 50.90–59.87
GLS regression Z=21.29, p<0.001, 95% CI [58.40–70.63].
ω
2 effect size of the timed CAPS=0.6794 (extremely strong substantive significance).
scores were strongly correlated with the 1-week post-treatment
CAPS scores (0.66, p< 0.001) and moderately correlated with the
3-month post-treatment CAPS scores (0.45, p< 0.05). The 1-week
post-treatment CAPS scores were strongly correlated with the
3-month post-treatment CAPS scores (0.71), p< 0.001.
We decided to use a bootstrap estimation of the SEs in lin-
ear regression. We drew 1000 random samples with replace-
ment from the dataset and examined the distribution of each
parameter using the variance of that distribution to estimate
a SE. The bootstrap estimation did not demonstrate statisti-
cal significance of the pre-treatment CAPS as a predictor of
the 3-month post-treatment CAPS (z= 0.18, p= 0.86, 95% CI
[ 0.51, 0.42]). However, it did demonstrate statistical signifi-
cance of the 1-week post-treatment CAPS as a predictor of the
3-month post-treatment CAPS scores (z= 3.38, p< 0.001, 95%
CI [0.33, 1.25]). This confirmed what was found in Figure 2.
We wanted to estimate any unknown parameters in our linear
regression model of our 3 treatment groups by using a random
effects GLS technique. The GLS demonstrated that with our
26 subjects in the 3 timed groups the R2 within groups was
0.000, R2 between groups was 0.000, and overall the R2 was
0.000. The GLS regression was strongly statistically significant
z= 21.29, p< 0.001, 95% CI [58.7, 70.63]. An ANOVA of the
CAPS tests over time predicted 79% of the variation in the 3-
month post-treatment CAPS scores R2= 0.79, adjusted R2= 0.68.
There was a statistically significant relationship between the
pre and 1-week post-treatment and the 3-month post-treatment
CAPS [F(1,77)= 7.12, p< 0.001]. We calculated the R2 for
the timed CAPS scores independent of the model (F= 26.67,
p< 0.0001) and adjusted for the potential bias in the F statistic
by calculating the Huynh–Feldt "= 0.8800, Greenhouse–Geisser
"= 0.8285, and Box’s conservative "= 0.5000. These adjust-
ments revealed that all three of the adjustments revealed an F
of 26.67 with a strong statistical significance of <0.001. The
omega squared ES of the timed CAPS tests= 0.6794 representing
extremely strong substantive significance. The linear predictive
margins over time demonstrated strong statistical significance
for all timed CAPS tests. The pre-treatment CAPS t(78)= 34.76,
p< 0.001, 95% CI [73.09, 82.06], 1-week post-treatment CAPS
t(78)= 27.37, p< 0.001, 95% CI [56.59, 65.56], and the 3-month
post-treatment CAPS t(78)= 24.82, p< 0.001, 95% CI [50.90,
59.87] (Table 6).
Discussion
We accomplished the specific aim of our study by analyz-
ing the difference in the pre-treatment, 1-week and 3-month
post-treatment CAPS severity scores in our subjects as outcomes
to compare the effectiveness of the subject’s specific novel brain
and VR interventions. We expected to find both statistical and
substantive significant decreases in CAPS severity scores similar
to our pilot study and we did. However, we expected to see a
drop of the treatment effect at 3months after treatment but found
that the subjects continued to improve. We attribute this to the
increased brain activation resulting from an increased ability to
function in activities of daily living. Our subjects were able to
embrace activities, both cognitively and physically that they were
not previously able to navigate due to the severity of their PTSD
symptoms. Increased activity because of decreased suffering has
continued to be associated with a further diminution of PTSD
severity scores.
This investigation has analyzed the use of a subject’s specific
novel brain and VR treatment modality in PTSD patients who
have suffered combat-related traumatic brain injuries immediately
and over time after treatment. In general, we obtained both strong
statistical and substantive significant outcomes. The treatment
of this disorder as a physical injury with brain and vestibular
non-invasive and non-pharmaceutical applications over a 2-week
program has lasting positive effects. Further, a successful 2-week
treatment period may be associated with significant savings of
cost, time, and disability when compared to longer therapy pro-
grams. There may be a stigma associated with having a neu-
ropsychiatric diagnosis of PTSD that might be lessened if a phys-
icality of etiology similar to that commonly accepted in mTBI
is embraced. Our investigation has the promise of development
of superior outcomes of treatments in this area that will benefit
a global society. The continued decrease of PTSD severity over
time is an exciting reality that is uniquely associated with this
novel approach to the treatment of a disorder that has personal,
familial, and societal consequences. The length of the treatment
intervention involved (2weeks) is less that other currently avail-
able treatments and has profound implications on cost, duration
of disability, and outcomes in the treatment of PTSD in combat
veterans.
Strengths and Weaknesses of the Study
The observed clinical results of our treatments might change the
direction of therapy sponsored by government and private agen-
cies. We have been successful in obtaining long-term (3months)
outcomes that have answered an important clinical question of
treatment effect. This study did not include any female subjects.
We are aware that many women are military veterans who have
suffered blast injuries and resultant PTSD; however, we wanted to
verify the results of our previous study andpreferred not to include
female subjects to avoid adding another possible confounding
factor (the gender). Future research is needed to verify if similar
outcomes can be obtained with women.
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